Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11)

BACKGROUND: In this study, we evaluated the association between genetic polymorphisms of 23 genes associated with gemcitabine metabolism and the clinical efficacy of gemcitabine in breast cancer patients. PATIENTS AND METHODS: This prospective, pharmacogenetic study was conducted in cooperation with...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, E.H., Kim, J.-Y., Im, S.-A., Jung, K.H., Sohn, J., Lee, K.S., Chae, Y.S., Lee, K.H., Kim, J.H., Jang, J.-H., Ahn, J.H., Park, M.S., Lee, S.-Y., Park, Y.H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8390551/
https://www.ncbi.nlm.nih.gov/pubmed/34438242
http://dx.doi.org/10.1016/j.esmoop.2021.100236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8390551/
https://www.ncbi.nlm.nih.gov/pubmed/34438242
http://dx.doi.org/10.1016/j.esmoop.2021.100236

Ejemplares similares